| 17.01.2023 14:05 | AVCT | Second Price Monitoring Extn | RNS |
| 17.01.2023 14:00 | AVCT | Price Monitoring Extension | RNS |
| 17.01.2023 11:05 | AVCT | Second Price Monitoring Extn | RNS |
| 17.01.2023 11:00 | AVCT | Price Monitoring Extension | RNS |
| 17.01.2023 09:05 | AVCT | Second Price Monitoring Extn | RNS |
| 17.01.2023 09:00 | AVCT | Price Monitoring Extension | RNS |
| 17.01.2023 07:00 | AVCT | Successful Completion of Fourth Dose Escalation | RNS |
| 16.01.2023 10:15 | AVCT | Block Listing Application to AIM | RNS |
| 19.12.2022 07:00 | AVCT | Avacta to Host Therapeutics Division Science Day | RNS |
| 08.11.2022 13:51 | AVCT | Avacta raises GBP64 million to finance Launch Diagnostics purchase | Alliance |
| 08.11.2022 07:01 | AVCT | Director/PDMR Shareholding | RNS |
| 08.11.2022 07:00 | AVCT | Result of the Open Offer | RNS |
| 31.10.2022 13:32 | AVCT | Avacta to Present at Theranostics FAP Summit | RNS |
| 31.10.2022 11:05 | AVCT | Second Price Monitoring Extn | RNS |
| 31.10.2022 11:00 | AVCT | Price Monitoring Extension | RNS |
| 28.10.2022 07:00 | AVCT | Block Listing Six Monthly Return | RNS |
| 20.10.2022 08:01 | AVCT | Director/PDMR Shareholding | RNS |
| 20.10.2022 08:01 | AVCT | Admission of the Company’s Ordinary Shares | RNS |
| 20.10.2022 07:00 | AVCT | Posting of the Company’s Open Offer Circular | RNS |
| 18.10.2022 12:40 | AVCT | Avacta plans to raise GBP62 million; buys Launch Diagnostics | Alliance |
| 18.10.2022 11:49 | AVCT | Result of Placing | RNS |
| 18.10.2022 09:16 | AVCT | Private CB and ABB Launch | RNS |
| 18.10.2022 09:14 | AVCT | Proposed acquisition of Launch Diagnostics | RNS |
| 29.09.2022 11:30 | AVCT | Avacta narrows loss, multiplies revenue thanks to Therapeutics divison | Alliance |
| 29.09.2022 07:00 | AVCT | Interim Results for the Period Ended 30 June 2022 | RNS |
| 26.09.2022 07:00 | AVCT | Notice of Results | RNS |
| 05.09.2022 11:07 | BLOE, JLP, AVCT | AIM WINNERS & LOSERS: Avacta gets approval; Jubilee's Roan at capacity | Alliance |
| 05.09.2022 10:10 | AVCT | Avacta shares up as drug approved for soft tissue sarcoma treatment | Alliance |
| 05.09.2022 07:00 | AVCT | AVA6000 receives Orphan Drug Designation from FDA | RNS |
| 01.09.2022 12:01 | AVCT | Avacta cancer drug candidate AVA6000 advances to fourth dose cohort | Alliance |
| 01.09.2022 07:00 | AVCT | Phase I study of AVA6000 advances to fourth cohort | RNS |
| 21.07.2022 12:17 | AVCT | Avacta joint venture completes funding for lead cell therapy programme | Alliance |
| 21.07.2022 07:00 | AVCT | AffyXell successfully completes funding round | RNS |
| 30.06.2022 11:22 | AVCT | Avacta's partner LG Chem renews licence to develop Affimer platform | Alliance |
| 30.06.2022 07:00 | AVCT | LG Chem renews license triggers payment to Avacta | RNS |
| 29.06.2022 11:38 | DELT, SAE, AVCT | AIM WINNERS & LOSERS: Deltic rises on Shell deal; Windar down on delay | Alliance |
| 29.06.2022 10:21 | AVCT | Avacta shares up as cancer drug AVA6000 advances to third dose cohort | Alliance |
| 29.06.2022 09:05 | AVCT | Second Price Monitoring Extn | RNS |
| 29.06.2022 09:00 | AVCT | Price Monitoring Extension | RNS |
| 29.06.2022 07:00 | AVCT | Second dose escalation in phase 1 trial of AVA6000 | RNS |
| 23.06.2022 16:41 | AVCT | Second Price Monitoring Extn | RNS |
| 23.06.2022 16:36 | AVCT | Price Monitoring Extension | RNS |
| 23.06.2022 16:27 | AVCT | Result of Annual General Meeting | RNS |
| 16.06.2022 16:41 | AVCT | Second Price Monitoring Extn | RNS |
| 16.06.2022 16:36 | AVCT | Price Monitoring Extension | RNS |
| 16.06.2022 16:03 | ZNWD, TND, RBGP | UK shareholder meetings calendar - next 7 days | Alliance |
| 31.05.2022 07:00 | AVCT | Posting of Annual Report and Notice of AGM | RNS |
| 16.05.2022 14:04 | AVCT | IN BRIEF: Avacta joint venture expands partnership with GenScript | Alliance |
| 16.05.2022 12:00 | AVCT | AffyXell expands partnership with GenScript ProBio | RNS |
| 11.05.2022 07:00 | AVCT | London Therapeutics headquarters established | Reach |
| 06.05.2022 07:00 | AVCT | Block Listing Application to AIM (update) | RNS |
| 28.04.2022 13:53 | AVCT | Block Listing Application to AIM | RNS |
| 14.04.2022 17:01 | AVCT | Issue of Equity and Total Voting Rights | RNS |
| 14.04.2022 11:29 | AVCT | Issue of Equity and Total Voting Rights | RNS |
| 13.04.2022 17:33 | AVCT | Avacta increases shareholding in drug developer AffyXell to 22% | Alliance |
| 13.04.2022 07:00 | AVCT | AffyXell milestone and increased equity stake | RNS |
| 12.04.2022 07:00 | AVCT | Poster presented at the AACR available to download | RNS |
| 11.04.2022 16:41 | AVCT | Second Price Monitoring Extn | RNS |
| 11.04.2022 16:35 | AVCT | Price Monitoring Extension | RNS |
| 11.04.2022 14:05 | AVCT | Second Price Monitoring Extn | RNS |
| 11.04.2022 14:00 | AVCT | Price Monitoring Extension | RNS |
| 08.04.2022 13:57 | AVCT | Issue of Equity and Total Voting Rights | RNS |
| 08.04.2022 11:28 | JET2, AVCT, JNEO | AIM WINNERS & LOSERS: Sensyne Health drops amid AIM delisting warning | Alliance |
| 08.04.2022 10:37 | AVCT | Avacta joint venture to collaborate with Chinese biological company | Alliance |
| 08.04.2022 07:00 | AVCT | AffyXell partners with Biocytogen and KNTSC | RNS |
| 07.04.2022 16:31 | AVCT | Issue of Equity and Total Voting Rights | RNS |
| 06.04.2022 10:23 | AVCT | IN BRIEF: Avacta widens annual loss on research, manufacturing costs | Alliance |
| 06.04.2022 07:00 | AVCT | Preliminary Results | RNS |
| 30.03.2022 16:41 | AVCT | Second Price Monitoring Extn | RNS |
| 30.03.2022 16:35 | AVCT | Price Monitoring Extension | RNS |
| 30.03.2022 07:00 | AVCT | Notice of Results and Investor Presentation | RNS |
| 29.03.2022 07:00 | AVCT | AVA6000 data poster presentation at AACR | RNS |
| 21.03.2022 07:00 | AVCT | Directorate Change | RNS |
| 16.03.2022 11:38 | AVCT | Avacta sells veterinary division to Vimian for up to GBP2.3 million | Alliance |
| 16.03.2022 07:00 | AVCT | Vimian acquires Avacta’s Animal Health Division | RNS |
